Exome sequencing of oral leukoplakia and oral squamous cell carcinoma implicates DNA damage repair gene defects in malignant transformation.


Journal

Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118

Informations de publication

Date de publication:
09 2019
Historique:
received: 09 04 2019
revised: 28 05 2019
accepted: 05 07 2019
pubmed: 20 8 2019
medline: 1 7 2020
entrez: 19 8 2019
Statut: ppublish

Résumé

To map the genomic pathways of patients with oral leukoplakia (OLK) which transformed to cancer (progressive) and those which did not (non-progressive), and to compare their exomic profiles. Whole exome sequencing was performed on 42 sequential samples from five progressive and eight non-progressive patients. Association of genomic variant frequencies with progression or lesion severity were analysed by non-parametric tests (Kruskal-Wallis and Mann-Whitney-Wilcoxon) and multivariate sparse partial least squares discriminant analysis (sPLS-DA). Enrichment analysis was used to characterise the effect of mutations upon biological pathways. Confirmatory studies used qPCR and immunohistochemistry. Using sPLS-DA, the variant frequency of a small number of genes could be used to classify the samples based on lesion severity or progressive status. Enrichment analysis showed that DNA damage repair gene related pathways were highly impacted in lesions which progressed to cancer. Multivariate analysis of a set of 148 DNA damage repair genes could be used to classify progressive lesions using mutation frequency. BRCA1, BRCA2 and other double strand break (DSB) repair Fanconi anaemia (FA)/BRCA pathway genes were prominent contributors to this classification. Patients with progressive and non-progressive OLK can be differentiated using the frequency of exomic variants, particularly in DNA damage repair pathway genes. To our knowledge, this is the first report of FA/BRCA (DSB) pathway involvement in malignant transformation of OLK to oral squamous cell carcinoma (OSCC).

Identifiants

pubmed: 31422212
pii: S1368-8375(19)30238-6
doi: 10.1016/j.oraloncology.2019.07.005
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

42-50

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Camile S Farah (CS)

Australian Centre for Oral Oncology Research & Education, Perth, WA 6009, Australia; UWA Dental School, University of Western Australia, Perth, WA 6009, Australia; UQ Centre for Clinical Research, The University of Queensland, Herston, QLD 4029, Australia. Electronic address: camile@oralmedpath.com.au.

Maryam Jessri (M)

UWA Dental School, University of Western Australia, Perth, WA 6009, Australia; UQ Centre for Clinical Research, The University of Queensland, Herston, QLD 4029, Australia.

Nigel C Bennett (NC)

UQ Centre for Clinical Research, The University of Queensland, Herston, QLD 4029, Australia.

Andrew J Dalley (AJ)

UQ Centre for Clinical Research, The University of Queensland, Herston, QLD 4029, Australia.

Kate D Shearston (KD)

UWA Dental School, University of Western Australia, Perth, WA 6009, Australia.

Simon A Fox (SA)

UWA Dental School, University of Western Australia, Perth, WA 6009, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH